Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis



Status:Completed
Conditions:Arthritis, Cancer, Cancer, Rheumatoid Arthritis, Brain Cancer, Neurology
Therapuetic Areas:Neurology, Oncology, Rheumatology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:April 2005
End Date:June 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.

The purpose of this study is to determine whether [18F]FHBG is suitable for use as an
imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy
trials. In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in
patients.

The success of cell and gene therapy depends on specific targeting of the therapeutic gene
or cell that is administered to the patient. Our goal is to develop an imaging method to
non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in
the design of better protocols and potentially reduce side-effects of cell and gene therapy.

Inclusion Criteria:

- Clinical diagnosis of brain tumor or rheumatoid arthritis

Exclusion Criteria:

- Below 18 years of age
We found this trial at
2
sites
Stanford University School of Medicine
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
University of California at Los Angeles
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials